SCHEMBL4622178

SCHEMBL4622178

Cc1noc(=O)c2ccc(NC(=O)C(=O)CC3(c4ccccc4Cl)CCCC3)cc12

nearest known ligand 0.49

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 20/20 0.49
PGR P06401 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5645631 0.96 NR3C1 (0.48) NR3C1PGR
SCHEMBL6585630 0.86 NR3C1 (0.51) NR3C1PGR
SCHEMBL6584187 0.85 NR3C1 (0.52) NR3C1PGR
SCHEMBL6585728 0.83 NR3C1 (0.51) NR3C1PGR
SCHEMBL5642602 0.82 NR3C1 (0.45) NR3C1PGR
SCHEMBL5642710 0.81 NR3C1 (0.69) NR3C1
SCHEMBL7170059 0.81 NR3C1 (0.69) NR3C1
SCHEMBL5642293 0.80 NR3C1 (0.69) NR3C1
SCHEMBL5077893 0.79 NR3C1 (0.48) NR3C1PGR
SCHEMBL14604853 0.79 NR3C1 (0.52) NR3C1PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1440976-B1 Modified aminoacids, pharmaceuticals containing these compounds and method for their production BOEHRINGER INGELHEIM PHARMA (DE) 2008-07-23 EP claimed
EP-1529051-B1 GROUP 4 METAL COMPLEXES CONTAINING 4-ARYL-SUBSTITUTED, TRICYCLIC INDENYL DERIVATIVES DOW GLOBAL TECHNOLOGIES INC (US) 2008-07-02 EP claimed
EP-1017701-B1 CYCLOPENTAPHENANTHRENYL TITANIUM COMPLEXES AND POLYMERIZATION PROCESS DOW GLOBAL TECHNOLOGIES INC (US) 2003-03-19 EP claimed
EP-0874860-B1 SUBSTITUTED INDENYL CONTAINING METAL COMPLEXES AND OLEFIN POLYMERIZATION PROCESS DOW CHEMICAL CO (US) 2002-11-13 EP claimed
EP-0946575-B1 FUSED RING SUBSTITUTED INDENYL METAL COMPLEXES AND POLYMERIZATION PROCESS DOW CHEMICAL CO (US) 2001-10-10 EP claimed
EP-0019369-B1 ISOTHIOUREIDO ISOINDOLEDIONES, PROCESS FOR THEIR PREPARATION AND USE AS PLANT REGULATORS Gulf Oil Corporation (US) 1984-03-07 EP claimed
EP-2904034-B1 METHOD FOR PREPARING A STATISTICAL COPOLYMER BASED ON DIENE MONOMERS AND CYCLIC CARBOSILANE MONOMERS MICHELIN & CIE (FR) 2018-04-18 EP disclosed
EP-1902049-A2 NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS Bayer Schering Pharma Aktiengesellschaft (DE) 2008-03-26 EP disclosed
US-20070010514-A1 Non-steroidal progesterone receptor modulators BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-01-11 US disclosed
WO-2006136461-A2 NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2006-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010514-A1 Non-steroidal progesterone receptor modulators PGR, PGRMC1, CYP19A1 NR3C1 69/4885PGR 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.